Does Pacific Edge have a target on its back?

Does Pacific Edge have a target on its back?
Invested capital in Cxbladder makes for an 'attractive acquisition target' (Image: supplied)
Brent Melville
Cancer diagnostic company Pacific Edge could be ripe for a takeover, analysis by investment firm Bell Potter suggests.Bell Potter, the Australian adviser to Pacific Edge’s September listing on the ASX, kicked off coverage of the Dunedin-based company with a speculative buy recommendation this week, valuing it at A$1.10 ($1.19) a share. That’s an 18% premium to Tuesday’s ASX price of 93 Australian cents, and a firm advance on its NZX Tuesday close of 99 cents. Local investment house Jarden pegs the NZX target price at $1.1...

More Markets

Quashed opens the door for challenger insurers
Markets Risky Business

Quashed opens the door for challenger insurers

Turners-backed comparison site could hit key milestone by year-end.

Fonterra’s fascinating exec incentive scheme
Opinion

Stock & Trade: Fonterra’s fascinating exec incentive scheme

Winston Peters has questioned bonuses linked to Fonterra’s $4.2b sale.

Spot market power prices 'past their peak': Genesis
Markets

Spot market power prices 'past their peak': Genesis

Genesis has 1.1 million tonnes of coal stockpiled for use at the Huntly Power Station.

Open banking's red tape may stifle lenders' innovation: fintechs
Policy

Open banking's red tape may stifle lenders' innovation: fintechs

Fee-free open banking and levies may deter banks from innovating with new tech.